<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327495</url>
  </required_header>
  <id_info>
    <org_study_id>39738</org_study_id>
    <secondary_id>1R01AG037603-01</secondary_id>
    <nct_id>NCT01327495</nct_id>
  </id_info>
  <brief_title>PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate</brief_title>
  <acronym>PROS-2</acronym>
  <official_title>Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a three-month, randomized, placebo-controlled trial comparing
      the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the
      prostate in healthy men who are treated with acyline to block gonadal androgen production.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators overall goals are (i) to determine the relationship between serum and
      prostate tissue hormone concentrations in men in response to increasing doses of exogenous
      androgens; (ii) to determine the impact that alterations in serum and tissue testosterone
      concentrations have on prostate epithelial cell function and phenotype; and (iii) to
      determine the relationships between prostatic androgens and alterations in the tissue
      microenvironment. The investigators will perform a study in healthy, middle-aged men to
      address the following Specific Aims:

      Specific Aims: To compare the dose-response relationships between serum testosterone and
      intraprostatic androgens and androgen action, and serum testosterone and anabolic activity in
      healthy, middle-aged men.

      Hypothesis: The investigators hypothesize that very low levels of serum testosterone will
      lower concentrations of intraprostatic testosterone and dihydrotestosterone (DHT). However,
      when serum testosterone concentrations are within or even above the normal range there will
      be no significant increases in intraprostatic testosterone and dihydrotestosterone. In
      contrast, the investigators expect that anabolic activity will increase with increasing
      concentrations of circulating testosterone.

      Secondarily, the investigators hypothesize that increasing levels of serum testosterone
      beyond the low normal range will have little impact on androgen action within the prostate.

      Approach: The investigators will conduct a randomized, placebo-controlled trial in healthy
      men who are medically castrated and administered one of five different doses of testosterone
      gel (Androgel) for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate Tissue DHT Concentrations After Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>To measure intraprostatic dihydrotestosterone [DHT] levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Testosterone</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dihydrotestosterone (DHT)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate Tissue Testosterone Concentrations After Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>To measure intraprostatic testosterone levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Volume</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>IPSS score: 0-7 mildly symptomatic, 8-19 moderately symptomatic, 20-35 severely symptomatic</description>
  </secondary_outcome>
  <other_outcome>
    <measure>17-OHPreg</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>17-OHP</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Androstenedione</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Androsterone</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>DHEA</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pregnenolone</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Progesterone</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2:1.25g Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: 2.5g Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: 5g Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: 10g Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: 15g Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo acyline</intervention_name>
    <description>Placebo acyline subcutaneous injection every 2 weeks</description>
    <arm_group_label>Arm 1: Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>daily placebo testosterone gel applied transdermally x 12 weeks</description>
    <arm_group_label>Arm 1: Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone 1% gel 1.25 g</intervention_name>
    <description>testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks</description>
    <arm_group_label>Arm 2:1.25g Testosterone</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone 1% gel 2.5 g</intervention_name>
    <description>Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks</description>
    <arm_group_label>Arm 3: 2.5g Testosterone</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone 1% gel 5.0 g</intervention_name>
    <description>Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks</description>
    <arm_group_label>Arm 4: 5g Testosterone</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone 1% gel 10 g</intervention_name>
    <description>Testosterone 1% gel 10 g daily applied transdermally x 12 weeks</description>
    <arm_group_label>Arm 5: 10g Testosterone</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone 1% gel 15 g</intervention_name>
    <description>Testosterone 1% gel 15 g daily applied transdermally x 12 weeks</description>
    <arm_group_label>Arm 6: 15g Testosterone</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>300 ug/kg subcutaneous injection every 2 weeks</description>
    <arm_group_label>Arm 2:1.25g Testosterone</arm_group_label>
    <arm_group_label>Arm 3: 2.5g Testosterone</arm_group_label>
    <arm_group_label>Arm 4: 5g Testosterone</arm_group_label>
    <arm_group_label>Arm 5: 10g Testosterone</arm_group_label>
    <arm_group_label>Arm 6: 15g Testosterone</arm_group_label>
    <other_name>GNRH antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In good health, without severe systemic illness (i.e., renal, liver, cardiac or lung
        disease, cancer, insulin dependent diabetes)

          -  Male between the ages of 25 and 55 years old

          -  Able to understand and comply with protocol instructions and requirements

          -  International Prostate Symptom Score (IPSS) &lt;11

          -  Agrees to not donate blood during the study

          -  Normal serum total T, LH, FSH, urine analysis, COMP, CBC and sperm count

        Exclusion Criteria:

          -  History of, or current breast cancer or prostate cancer

          -  Clinically significant findings on digital rectal exam such as nodules, areas of
             induration or any other malignancy or abnormal prostate ultrasound

          -  History of invasive therapy for BPH

          -  Current or past treatment with a 5α-reductase inhibitor

          -  History of drug or alcohol abuse within the past 12 months

          -  History of a bleeding disorder or anticoagulation

          -  Skin disease that might interfere with T-gel absorption

          -  Participation in another drug study in the past 3 months

          -  A first-degree relative (i.e. father, brother) with a history of prostate cancer

          -  History of infertility or desire for fertility within 6 months, or current pregnant
             female partner

          -  Weight &gt;320 pounds or BMI &gt; 40

          -  PSA Level &gt; 2.1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie T Page, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>Dedicated to basic and clinical research primarily focusing on the male reproductive system</description>
  </link>
  <results_reference>
    <citation>Thirumalai A, Cooper LA, Rubinow KB, Amory JK, Lin DW, Wright JL, Marck BT, Matsumoto AM, Page ST. Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone. J Clin Endocrinol Metab. 2016 Jul;101(7):2937-44. doi: 10.1210/jc.2016-1483. Epub 2016 May 12.</citation>
    <PMID>27172434</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <results_first_submitted>February 15, 2017</results_first_submitted>
  <results_first_submitted_qc>September 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2017</results_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Stephanie T. Page</investigator_full_name>
    <investigator_title>Professor Department of Medicine, Division of Metabolism, Endocrinology and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Androgen replacement in men</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy males, 25-55 years old, were recruited via advertisement: flyers and newspaper ads at the University of Washington.</recruitment_details>
      <pre_assignment_details>98 screened. 28 screen fails (or did not finish screen). 8 subjects dropped out prior to drug start. 62 subjects started drug. 7 subjects dropped after drug start/pre-drug finish. 2 dropped after finishing study drug, but prior to prostate biopsy. 2 subjects dropped from analysis for non-compliance. 51 completed entire study, included in analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1 (Placebo Acyline &amp; Placebo T Gel )</title>
          <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 (Acyline &amp; 1.25g Testosterone Gel)</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Arm 3 (Acyline &amp; 2.5g Testosterone Gel)</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="P4">
          <title>Arm 4 (Acyline &amp; 5g Testosterone Gel)</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="P5">
          <title>Arm 5 (Acyline &amp; 10g Testosterone Gel)</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="P6">
          <title>Arm 6 (Acyline &amp; 15g Testosterone Gel)</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8">1 dropped due to decreased libido &amp; energy, 1 dropped due to too much pain with acyline injections</participants>
                <participants group_id="P2" count="9">1 subject declined prostate biopsy &amp; no-showed to final visit, 1 subject dropped d/t elevated LFTs.</participants>
                <participants group_id="P3" count="8">1 withdrawn due to injection AE. 1 drop-out (declined prostate biopsy and final visit).</participants>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="8">1 dropped out pre drug finish, 2 non-compliant subjects dropped</participants>
                <participants group_id="P6" count="9">1 subject withdrawn d/t elevated LFTs, 1 dropped out d/t ski accident</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>62 subjects started treatment, 11 dropped after drug start &amp; pre-study exit visit (7 dropped post-drug start but pre-drug finish, 2 dropped after drug finish but pre-prostate biopsy, 2 dropped for non-compliance). 51 participants included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Arm 3</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Arm 4</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="B5">
          <title>Arm 5</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="B6">
          <title>Arm 6</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="34" upper_limit="48"/>
                    <measurement group_id="B2" value="45" lower_limit="41" upper_limit="46"/>
                    <measurement group_id="B3" value="46" lower_limit="39" upper_limit="51"/>
                    <measurement group_id="B4" value="34" lower_limit="30" upper_limit="44"/>
                    <measurement group_id="B5" value="42" lower_limit="33" upper_limit="47"/>
                    <measurement group_id="B6" value="51" lower_limit="50" upper_limit="54"/>
                    <measurement group_id="B7" value="44" lower_limit="35" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg^m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="26" upper_limit="33"/>
                    <measurement group_id="B2" value="28" lower_limit="25" upper_limit="33"/>
                    <measurement group_id="B3" value="26" lower_limit="24" upper_limit="28"/>
                    <measurement group_id="B4" value="25" lower_limit="25" upper_limit="27"/>
                    <measurement group_id="B5" value="25" lower_limit="22" upper_limit="28"/>
                    <measurement group_id="B6" value="26" lower_limit="25" upper_limit="28"/>
                    <measurement group_id="B7" value="26" lower_limit="25" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Testosterone Level</title>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="450" lower_limit="315" upper_limit="516"/>
                    <measurement group_id="B2" value="448" lower_limit="345" upper_limit="509"/>
                    <measurement group_id="B3" value="554" lower_limit="462" upper_limit="730"/>
                    <measurement group_id="B4" value="419" lower_limit="387" upper_limit="505"/>
                    <measurement group_id="B5" value="482" lower_limit="429" upper_limit="591"/>
                    <measurement group_id="B6" value="452" lower_limit="396" upper_limit="536"/>
                    <measurement group_id="B7" value="459" lower_limit="390" upper_limit="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DHT Level</title>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="27" upper_limit="47"/>
                    <measurement group_id="B2" value="37" lower_limit="24" upper_limit="44"/>
                    <measurement group_id="B3" value="43" lower_limit="39" upper_limit="59"/>
                    <measurement group_id="B4" value="39" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B5" value="49" lower_limit="44" upper_limit="55"/>
                    <measurement group_id="B6" value="36" lower_limit="28" upper_limit="53"/>
                    <measurement group_id="B7" value="40" lower_limit="28" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lutenizing Hormone</title>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="3" upper_limit="4.5"/>
                    <measurement group_id="B2" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="B3" value="4" lower_limit="2" upper_limit="5.5"/>
                    <measurement group_id="B4" value="3" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="B5" value="4" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="B6" value="3" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="B7" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FSH</title>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="4" upper_limit="8.5"/>
                    <measurement group_id="B2" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="B3" value="5" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="B4" value="5" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="B5" value="5.5" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="B6" value="7" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="B7" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematocrit</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="42" upper_limit="45"/>
                    <measurement group_id="B2" value="43" lower_limit="41" upper_limit="44"/>
                    <measurement group_id="B3" value="43" lower_limit="42" upper_limit="44"/>
                    <measurement group_id="B4" value="44" lower_limit="41" upper_limit="46"/>
                    <measurement group_id="B5" value="45" lower_limit="42" upper_limit="45"/>
                    <measurement group_id="B6" value="43" lower_limit="41" upper_limit="44"/>
                    <measurement group_id="B7" value="43" lower_limit="41" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen (PSA)</title>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.80" lower_limit="0.61" upper_limit="0.91"/>
                    <measurement group_id="B2" value="0.71" lower_limit="0.66" upper_limit="0.88"/>
                    <measurement group_id="B3" value="1.09" lower_limit="0.75" upper_limit="1.25"/>
                    <measurement group_id="B4" value="0.74" lower_limit="0.34" upper_limit="0.86"/>
                    <measurement group_id="B5" value="0.67" lower_limit="0.41" upper_limit="0.91"/>
                    <measurement group_id="B6" value="0.69" lower_limit="0.35" upper_limit="0.91"/>
                    <measurement group_id="B7" value="0.75" lower_limit="0.42" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate volume</title>
          <units>cm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="16" upper_limit="22"/>
                    <measurement group_id="B2" value="19" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="B3" value="17" lower_limit="17" upper_limit="21"/>
                    <measurement group_id="B4" value="17" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="B5" value="17" lower_limit="14" upper_limit="20"/>
                    <measurement group_id="B6" value="19" lower_limit="15" upper_limit="19"/>
                    <measurement group_id="B7" value="18" lower_limit="14" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Prostate Symptom Score (IPSS)</title>
          <description>0-7 mildly symptomatic, 8-19 moderately symptomatic, 20-35 severely symptomatic</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="1.5" upper_limit="3"/>
                    <measurement group_id="B2" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="2" lower_limit="0" upper_limit="4.25"/>
                    <measurement group_id="B4" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="B5" value="1.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="B6" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B7" value="2" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prostate Tissue DHT Concentrations After Treatment</title>
        <description>To measure intraprostatic dihydrotestosterone [DHT] levels</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Placebo Acyline Inject &amp; Placebo Testosterone Gel</title>
            <description>Placebo acyline subcutaneous injection every 2 weeks for 12 weeks &amp; daily placebo testosterone (T) gel applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 1.25g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 1.25g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 2.5</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 2.5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 5g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 10g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 10g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 15g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 15g applied transdermally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Tissue DHT Concentrations After Treatment</title>
          <description>To measure intraprostatic dihydrotestosterone [DHT] levels</description>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" lower_limit="3.75" upper_limit="4.62"/>
                    <measurement group_id="O2" value="4.26" lower_limit="2.7" upper_limit="5.57"/>
                    <measurement group_id="O3" value="2.99" lower_limit="2.57" upper_limit="3.79"/>
                    <measurement group_id="O4" value="3.88" lower_limit="3.61" upper_limit="4.476"/>
                    <measurement group_id="O5" value="4.12" lower_limit="2.04" upper_limit="6.30"/>
                    <measurement group_id="O6" value="5.11" lower_limit="4.4" upper_limit="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Testosterone</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Placebo Acyline Inject &amp; Placebo Testosterone Gel</title>
            <description>Placebo acyline subcutaneous injection every 2 weeks for 12 weeks &amp; daily placebo testosterone (T) gel applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 1.25g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 1.25g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 2.5</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 2.5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 5g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 10g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 10g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 15g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 15g applied transdermally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.1" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.3" upper_limit="3.8"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.5" upper_limit="4.4"/>
                    <measurement group_id="O4" value="3.5" lower_limit="2.9" upper_limit="6.4"/>
                    <measurement group_id="O5" value="6.1" lower_limit="2.7" upper_limit="9.9"/>
                    <measurement group_id="O6" value="7.7" lower_limit="5.3" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dihydrotestosterone (DHT)</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Placebo Acyline Inject &amp; Placebo Testosterone Gel</title>
            <description>Placebo acyline subcutaneous injection every 2 weeks for 12 weeks &amp; daily placebo testosterone (T) gel applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 1.25g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 1.25g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 2.5</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 2.5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 5g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 10g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 10g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 15g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 15g applied transdermally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Dihydrotestosterone (DHT)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.3" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.5" upper_limit="1.2"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.7" upper_limit="1.2"/>
                    <measurement group_id="O5" value="1.5" lower_limit="0.6" upper_limit="2.5"/>
                    <measurement group_id="O6" value="1.8" lower_limit="1.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate Tissue Testosterone Concentrations After Treatment</title>
        <description>To measure intraprostatic testosterone levels</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/Placebo Acyline Inject &amp; Placebo Testosterone Gel</title>
            <description>Placebo acyline subcutaneous injection every 2 weeks for 12 weeks &amp; daily placebo testosterone (T) gel applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 1.25g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 1.25g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 2.5</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 2.5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 5g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 5g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 10g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 10g applied transdermally for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Acyline Inject Every 2 Weeks &amp; Daily T 1% Gel 15g</title>
            <description>Acyline (300ug/kg) subcutaneous injection every 2 weeks for 12 weeks &amp; daily 1% testosterone (T) gel 15g applied transdermally for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Tissue Testosterone Concentrations After Treatment</title>
          <description>To measure intraprostatic testosterone levels</description>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2275" upper_limit="0.535"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.11" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.125" lower_limit="0.1075" upper_limit="0.165"/>
                    <measurement group_id="O4" value="0.18" lower_limit="0.15" upper_limit="0.35"/>
                    <measurement group_id="O5" value="0.195" lower_limit="0.1275" upper_limit="0.77"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.22" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Antigen</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen</title>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.57" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.44" upper_limit="0.62"/>
                    <measurement group_id="O3" value="0.61" lower_limit="0.39" upper_limit="0.81"/>
                    <measurement group_id="O4" value="0.58" lower_limit="0.41" upper_limit="0.78"/>
                    <measurement group_id="O5" value="0.52" lower_limit="0.43" upper_limit="0.67"/>
                    <measurement group_id="O6" value="0.76" lower_limit="0.50" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Volume</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Volume</title>
          <units>cm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="18" upper_limit="22"/>
                    <measurement group_id="O2" value="18" lower_limit="14" upper_limit="22"/>
                    <measurement group_id="O3" value="19" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O4" value="15" lower_limit="14" upper_limit="17"/>
                    <measurement group_id="O5" value="16" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O6" value="20" lower_limit="16" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Prostate Symptom Score (IPSS)</title>
        <description>IPSS score: 0-7 mildly symptomatic, 8-19 moderately symptomatic, 20-35 severely symptomatic</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score (IPSS)</title>
          <description>IPSS score: 0-7 mildly symptomatic, 8-19 moderately symptomatic, 20-35 severely symptomatic</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.5" upper_limit="5.25"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="2.5" lower_limit="1.5" upper_limit="7.75"/>
                    <measurement group_id="O6" value="4" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>17-OHPreg</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>17-OHPreg</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="1.06" upper_limit="1.44"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.93" upper_limit="2.07"/>
                    <measurement group_id="O3" value="1.23" lower_limit="0.92" upper_limit="2.04"/>
                    <measurement group_id="O4" value="1.05" lower_limit="1.01" upper_limit="1.89"/>
                    <measurement group_id="O5" value="1.02" lower_limit="0.94" upper_limit="1.45"/>
                    <measurement group_id="O6" value="1.36" lower_limit="1.29" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>17-OHP</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>17-OHP</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.05" upper_limit="0.06"/>
                    <measurement group_id="O3" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                    <measurement group_id="O4" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                    <measurement group_id="O5" value="0.05" lower_limit="0.04" upper_limit="0.05"/>
                    <measurement group_id="O6" value="0.05" lower_limit="0.04" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Androstenedione</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Androstenedione</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.10" upper_limit="0.33"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.10" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.12" lower_limit="0.09" upper_limit="0.15"/>
                    <measurement group_id="O4" value="0.13" lower_limit="0.12" upper_limit="0.15"/>
                    <measurement group_id="O5" value="0.18" lower_limit="0.15" upper_limit="0.28"/>
                    <measurement group_id="O6" value="0.14" lower_limit="0.12" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Androsterone</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Androsterone</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.14" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.12" upper_limit="0.22"/>
                    <measurement group_id="O3" value="0.12" lower_limit="0.08" upper_limit="0.14"/>
                    <measurement group_id="O4" value="0.17" lower_limit="0.11" upper_limit="0.24"/>
                    <measurement group_id="O5" value="0.17" lower_limit="0.12" upper_limit="0.43"/>
                    <measurement group_id="O6" value="0.21" lower_limit="0.17" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>DHEA</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>DHEA</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="19.1" upper_limit="42.0"/>
                    <measurement group_id="O2" value="26.2" lower_limit="13.5" upper_limit="35.8"/>
                    <measurement group_id="O3" value="22.1" lower_limit="16.2" upper_limit="30.1"/>
                    <measurement group_id="O4" value="26.8" lower_limit="26.0" upper_limit="29.2"/>
                    <measurement group_id="O5" value="24.4" lower_limit="23.0" upper_limit="28.2"/>
                    <measurement group_id="O6" value="18.6" lower_limit="14.7" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pregnenolone</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnenolone</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="23.6" upper_limit="33.8"/>
                    <measurement group_id="O2" value="29.5" lower_limit="21.3" upper_limit="36.4"/>
                    <measurement group_id="O3" value="32.7" lower_limit="23.3" upper_limit="51.2"/>
                    <measurement group_id="O4" value="32.4" lower_limit="28.6" upper_limit="45.5"/>
                    <measurement group_id="O5" value="27.9" lower_limit="17.4" upper_limit="37.6"/>
                    <measurement group_id="O6" value="23.9" lower_limit="18.1" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Progesterone</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Arm 4</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Arm 5</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
          <group group_id="O6">
            <title>Arm 6</title>
            <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progesterone</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="0.06" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.06" upper_limit="0.09"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.04" upper_limit="0.09"/>
                    <measurement group_id="O4" value="0.08" lower_limit="0.07" upper_limit="0.13"/>
                    <measurement group_id="O5" value="0.09" lower_limit="0.08" upper_limit="0.12"/>
                    <measurement group_id="O6" value="0.07" lower_limit="0.07" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from day 1 through the end of study, Week 18. After the screening period, 12 weeks of treatment commenced for subjects who met inclusion/exclusion criteria, followed by a 6 week recovery period.</time_frame>
      <desc>The 62 subjects who started study drugs on Day 0 were monitored for adverse events. Nine subjects were discontinued prior to study end. Two subjects were not included in data analysis due to medication non-compliance. Hence, while there were 51 subjects included in the analysis, 62 subjects (all who started study drugs) were monitored for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
placebo acyline: Placebo acyline subcutaneous injection every 2 weeks
placebo gel: daily placebo testosterone gel applied transdermally x 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
Testosterone 1% gel 1.25 g: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
Testosterone 1% gel 2.5 g: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="E4">
          <title>Arm 4</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
Testosterone 1% gel 5.0 g: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="E5">
          <title>Arm 5</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
testosterone 1% gel 10 g: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
        <group group_id="E6">
          <title>Arm 6</title>
          <description>Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
testosterone 1% gel 15 g: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Acyline: 300 ug/kg subcutaneous injection every 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased libido</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Increased libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Semen changes (decreased ejaculation volume</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nipple discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood in semen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to Acyline</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Discomfort at injection site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hot flashes/night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mood changes (irritability)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Decreased energy, fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin changes (acne, rash at site of T gel</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea, vomiting, abnormal bowl movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injuries/accidents</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bruise at injection site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver funtion tests</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory infection/symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Page, MD, PhD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-616-0483</phone>
      <email>page@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

